Gene transfer in experimental medicine.
Gene transfer technology has many potential applications in medicine. Phase I and phase II gene-based clinical trials have been conducted for the treatment of cancer, monogenic disorders, some neurodegenerative illnesses, cardiopathies and infectious diseases. A phase I gene therapy clinical trial has recently been approved for the treatment of Parkinson's disease, while preclinical studies are in progress to develop gene-based interventions for the treatment of Alzheimer's disease and Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, and diabetes type 1 and type 2. A number of gene transfer models have been generated for gene therapy and genetic immunization programs. Vector design is addressing several pressing issues in the matter of gene delivery improvement, stabilization of transgene expression and safety. This is necessary in order to achieve efficient gene-based therapeutic interventions. Indeed, considerable progress has been reported in the field of vector design, which has produced some encouraging results in clinical trials and preclinical studies. However, vector design should be further developed to allow for the successful application of gene transfer technology in therapy. This review summarizes the latest achievements and controversies in clinical trials and preclinical studies in the field of gene therapy.
Romano
Gaetano
G
Department of Neurosurgery, The Farber Institute for the Neurosciences, Jefferson Medical College, Thomas Jefferson University, Jefferson Hospital for the Neurosciences, 900 Walnut Street Suite 422, Philadelphia, PA 19107, USA. Gaetano.Romano@jefferson.edu
D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000009:adverse effects / Q000706:statistics & numerical data; D006805:Human Experimentation; D006801:Humans